[go: up one dir, main page]

FR19C1071I2 - DIHYDROPYRIDOPHTHALAZINONE POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS - Google Patents

DIHYDROPYRIDOPHTHALAZINONE POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS

Info

Publication number
FR19C1071I2
FR19C1071I2 FR19C1071C FR19C1071C FR19C1071I2 FR 19C1071 I2 FR19C1071 I2 FR 19C1071I2 FR 19C1071 C FR19C1071 C FR 19C1071C FR 19C1071 C FR19C1071 C FR 19C1071C FR 19C1071 I2 FR19C1071 I2 FR 19C1071I2
Authority
FR
France
Prior art keywords
dihydropyridophthalazinone
parp
adp
ribose
polymerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1071C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Technologies LLC
Original Assignee
Medivation Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies LLC filed Critical Medivation Technologies LLC
Publication of FR19C1071I1 publication Critical patent/FR19C1071I1/fr
Application granted granted Critical
Publication of FR19C1071I2 publication Critical patent/FR19C1071I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
FR19C1071C 2008-08-06 2019-12-03 DIHYDROPYRIDOPHTHALAZINONE POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS Active FR19C1071I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8668708P 2008-08-06 2008-08-06
US15103609P 2009-02-09 2009-02-09
US17308809P 2009-04-27 2009-04-27
EP09805360.6A EP2326650B9 (en) 2008-08-06 2009-07-27 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)

Publications (2)

Publication Number Publication Date
FR19C1071I1 FR19C1071I1 (en) 2020-01-17
FR19C1071I2 true FR19C1071I2 (en) 2020-10-16

Family

ID=41129519

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1071C Active FR19C1071I2 (en) 2008-08-06 2019-12-03 DIHYDROPYRIDOPHTHALAZINONE POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS

Country Status (32)

Country Link
US (7) US8012976B2 (en)
EP (3) EP2767537B1 (en)
JP (3) JP5984389B2 (en)
KR (1) KR101846029B1 (en)
CN (3) CN102171214B (en)
AR (1) AR072970A1 (en)
AU (1) AU2009279944B2 (en)
BR (1) BRPI0917119B1 (en)
CA (1) CA2732797C (en)
CY (3) CY1115022T1 (en)
DK (2) DK2767537T3 (en)
ES (2) ES2466565T3 (en)
FR (1) FR19C1071I2 (en)
GB (1) GB2462361A (en)
HK (2) HK1157755A1 (en)
HR (1) HRP20170982T1 (en)
HU (2) HUE035295T2 (en)
IL (1) IL211070A (en)
LT (2) LT2767537T (en)
LU (1) LUC00140I2 (en)
MX (1) MX2011001328A (en)
NL (1) NL301021I2 (en)
NO (1) NO2019042I1 (en)
NZ (1) NZ591166A (en)
PL (2) PL2767537T3 (en)
PT (2) PT2326650E (en)
SG (2) SG10201809895YA (en)
SI (2) SI2326650T1 (en)
SM (1) SMT201700312T1 (en)
TW (2) TWI448464B (en)
WO (1) WO2010017055A2 (en)
ZA (1) ZA201100897B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2767537T3 (en) * 2008-08-06 2017-06-19 Medivation Technologies Inc DIHYDROPYRIDOPHTHALAZINON INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
RU2604066C2 (en) 2008-12-19 2016-12-10 Вертекс Фармасьютикалз Инкорпорейтед Pyrazine derivatives used as atr kinase inhibitors
CN106943406A (en) * 2010-02-03 2017-07-14 麦迪韦逊科技有限公司 Dihydro pyrido phthalazines ketone inhibitors for poly- (ADP ribose) polymerase (PARP) of the treatment of PTEN gene delection relevant diseases
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
KR101826652B1 (en) * 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. Processes of synthesizing dihydropyridophthalazinone derivatives
WO2011130661A1 (en) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
JP5836367B2 (en) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as ATR kinase inhibitors
RU2598606C3 (en) * 2010-10-21 2021-12-20 МЕДИВЭЙШН ТЕКНОЛОДЖИЗ ЭлЭлСи CRYSTALLINE TOSILATE SALT (8S, 9R) -5-FLUORINE-8- (4-FLUOROPHENYL) -9- (1-METHYL-1H-1,2,4-TRIAZOL-5-YL) -8-9-DIHYDRO-2H -PIRIDO [4,3,2-DE] PHTHALAZIN-3 (7H) -ONE
WO2012166151A1 (en) * 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
KR102013133B1 (en) * 2011-09-30 2019-08-22 버텍스 파마슈티칼스 인코포레이티드 Processes for making compounds useful as inhibitors of atr kinase
CN108685922A (en) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 With ATR inhibitor for treating cancer of pancreas and non-small cell lung cancer
EA027241B1 (en) * 2011-12-31 2017-07-31 Бейджен, Лтд. Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
EP2797921B1 (en) * 2011-12-31 2017-09-06 BeiGene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
CN115813902A (en) 2012-01-20 2023-03-21 德玛公司 Use of substituted hexitols for the treatment of malignant tumors
NZ726671A (en) 2012-04-05 2018-04-27 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
US9855261B2 (en) 2012-11-08 2018-01-02 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
SI2968316T1 (en) 2013-03-13 2019-11-29 Forma Therapeutics Inc 2-hydroxy-1-(4-((4-phenylphenyl)carbonyl)piperazin-1-yl)ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
CN105916846A (en) * 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 Triazole intermediates useful in the synthesis of protected N-alkyltriazolecarbaldehydes
CN103772395B (en) * 2014-01-23 2016-05-11 中国药科大学 One class has PARP and suppresses active compound, Preparation Method And The Use
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015195740A1 (en) 2014-06-17 2015-12-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
US20170217921A1 (en) 2014-07-31 2017-08-03 Medivation Technologies, Inc. Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3341375B1 (en) 2015-08-25 2022-04-13 BeiGene, Ltd. Process for preparing parp inhibitor, crystalline forms, and uses thereof
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
CN110087730B (en) * 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 Treatment of cancer using a combination comprising a PARP inhibitor
JP6541635B2 (en) * 2016-10-28 2019-07-10 ベイジーン リミテッド Fused Tetracyclic or Fused Pentacyclic Dihydrodiazepinocarbazolones as PARP Inhibitors
CN108210461A (en) * 2016-12-16 2018-06-29 中国科学院上海药物研究所 A kind of Talazoparib pharmaceutical compositions and its application
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
CN107573341B (en) * 2016-12-29 2020-08-14 广州丹康医药生物有限公司 Novel fused ring compound as PARP inhibitor, preparation method and application thereof
CN107556312B (en) * 2016-12-29 2020-04-10 广州丹康医药生物有限公司 Novel fused ring compound with PARP inhibitory activity, preparation method and use thereof
US10899763B2 (en) 2017-02-28 2021-01-26 Beigene, Ltd. Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
WO2018205938A1 (en) * 2017-05-08 2018-11-15 广州丹康医药生物有限公司 Parp inhibitor, pharmaceutical composition, preparation method and use thereof
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US20200254091A1 (en) 2017-10-13 2020-08-13 Merck Patent Gmbh Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist
TW201938165A (en) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 Methods and combination therapy to treat cancer
CN110272419A (en) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 Dihydro pyrido phthalazinone derivatives, preparation method and application
CN108341792B (en) * 2018-04-28 2021-09-17 苏州莱克施德药业有限公司 Preparation method of Volasertib intermediate 1-cyclopropyl methyl piperazine
CN108676888B (en) * 2018-07-12 2022-01-28 吉林大学 Reagent kit and system for predicting susceptibility of lung malignant tumor
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1H-BENZO[D]IMIDAZOLE-5-YL)BENZOYL)PIPERAZINE-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2020095184A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combinations for treating cancer
CN114206864B (en) 2019-05-14 2024-05-24 苏州四体康宸医药科技有限公司 Quinazoline-2, 4-dione derivatives as PARP inhibitors
BR112021022008A2 (en) 2019-05-14 2022-05-17 Nuvation Bio Inc Anticancer nuclear hormone receptor targeting compounds
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN111116514B (en) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 Preparation method of 1-cyclopropanecarbonyl piperazine hydrochloride
WO2021181233A2 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
JP2023548896A (en) 2020-11-13 2023-11-21 ファイザー・インク Talazoparib soft gelatin capsule dosage form
CN116802321A (en) 2020-12-07 2023-09-22 辉瑞公司 Methods to identify tumors that are sensitive to talazopanib treatment and how to treat them
WO2022204184A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4313034A1 (en) 2021-03-24 2024-02-07 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
EP4319755A1 (en) * 2021-04-08 2024-02-14 Board of Regents, The University of Texas System Compounds and methods for theranostic targeting of parp activity
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4089093A1 (en) * 2021-05-12 2022-11-16 Eberhard Karls Universität Tübingen Medizinische Fakultät Radiosynthesis of [18f] talazoparib
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
AU2023279251A1 (en) 2022-06-01 2024-12-05 Glaxosmithkline Intellectual Property (No.4) Limited Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2023239789A1 (en) * 2022-06-08 2023-12-14 Valo Health, Inc. Tricyclic phthalazinone parp inhibitors and methods of use
CN115572218B (en) * 2022-08-29 2024-04-16 江阴勒森生物科技有限公司 Preparation method of 2-bromo-3-hydroxybenzaldehyde and related chemiluminescent substrate intermediate thereof
TW202425975A (en) 2022-10-02 2024-07-01 美商輝瑞大藥廠 Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
TW202425976A (en) 2022-12-17 2024-07-01 美商輝瑞大藥廠 Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
CN116283924B (en) * 2023-01-16 2024-07-26 四川效佳科技有限公司 Recrystallization method of rizatriptan benzoate with pharmaceutical grade purity

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106631A (en) * 1870-08-23 Improvement in seed-planter
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (en) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd 2-quinolone derivative
US5328905A (en) * 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
PT705902E (en) 1994-08-12 2002-05-31 Univ Utah Res Found GENE OF SUSCEPTIBILITY FOR BREAST AND OVARY CANCER, LINKED TO 17Q.
DE69521002T3 (en) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutations of the 17q associated ovarian and breast cancer susceptibility gene
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (en) 1996-12-13 1998-06-18 Tanabe Seiyaku Co PYRIDINES, THEIR PRODUCTS AND THE INTERMEDIETS FOR THE PRODUCTION
DE19727410A1 (en) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3- (5-tetrazolylcarbonyl) -2-quinolones and crop protection agents containing them
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (en) 1999-05-11 2000-11-16 Basf Ag Use of phthalazine derivatives
JP2001302669A (en) 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd Tricyclic phthalazinone derivative
JP2002284699A (en) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd Remedies for photoreceptor degenerative diseases
AR036081A1 (en) 2001-06-07 2004-08-11 Smithkline Beecham Corp COMPOSITE OF 1,2-DIHYDROQUINOLINE, ITS USE TO PREPARE A PHARMACEUTICAL COMPOSITION, METHODS TO PREPARE IT AND N-RENTED 2-AMINOBENZOIC ACID OF UTILITY AS INTERMEDIARY IN SUCH METHODS
SE0102315D0 (en) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
CA2476406A1 (en) 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
AU2003277674A1 (en) 2002-11-12 2004-06-03 Mochida Pharmaceutical Co., Ltd. Novel parp inhibitors
PL1633724T3 (en) 2003-03-12 2011-10-31 Kudos Pharm Ltd Phthalazinone derivatives
AU2004242947B2 (en) * 2003-05-28 2010-04-29 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
CN1918137B (en) 2004-02-18 2012-08-01 阿斯利康(瑞典)有限公司 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR20100007956A (en) 2007-05-03 2010-01-22 화이자 리미티드 2-pyridine carboxamide derivatives as sodium channel modulators
EP2178875A1 (en) 2007-08-22 2010-04-28 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
JP5439380B2 (en) * 2007-10-03 2014-03-12 エーザイ インク． PARP inhibiting compounds, compositions and methods of use
CN101998959B (en) 2008-02-06 2013-08-28 生物马林药物股份有限公司 Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP)
DK2767537T3 (en) 2008-08-06 2017-06-19 Medivation Technologies Inc DIHYDROPYRIDOPHTHALAZINON INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
US20110301350A1 (en) 2008-08-12 2011-12-08 Boehringer Ingelheim International Gmbh Process for preparing cycloalkyl-substituted piperazine compounds
CN106943406A (en) 2010-02-03 2017-07-14 麦迪韦逊科技有限公司 Dihydro pyrido phthalazines ketone inhibitors for poly- (ADP ribose) polymerase (PARP) of the treatment of PTEN gene delection relevant diseases
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
KR101826652B1 (en) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. Processes of synthesizing dihydropyridophthalazinone derivatives
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
RU2598606C3 (en) 2010-10-21 2021-12-20 МЕДИВЭЙШН ТЕКНОЛОДЖИЗ ЭлЭлСи CRYSTALLINE TOSILATE SALT (8S, 9R) -5-FLUORINE-8- (4-FLUOROPHENYL) -9- (1-METHYL-1H-1,2,4-TRIAZOL-5-YL) -8-9-DIHYDRO-2H -PIRIDO [4,3,2-DE] PHTHALAZIN-3 (7H) -ONE
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
CN105916846A (en) 2013-11-07 2016-08-31 麦迪韦逊科技有限公司 Triazole intermediates useful in the synthesis of protected N-alkyltriazolecarbaldehydes
US20170217921A1 (en) 2014-07-31 2017-08-03 Medivation Technologies, Inc. Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Also Published As

Publication number Publication date
WO2010017055A2 (en) 2010-02-11
KR101846029B1 (en) 2018-04-06
KR20110040973A (en) 2011-04-20
LUC00140I1 (en) 2019-12-13
IL211070A0 (en) 2011-04-28
EP2326650B1 (en) 2014-02-26
SI2767537T1 (en) 2017-08-31
EP2326650A2 (en) 2011-06-01
NL301021I2 (en) 2020-04-14
CN104478875B (en) 2017-04-12
EP3241832A1 (en) 2017-11-08
US20210069191A1 (en) 2021-03-11
HUE035295T2 (en) 2018-05-02
SMT201700312T1 (en) 2017-09-07
RU2011108493A (en) 2012-09-20
MX2011001328A (en) 2011-04-04
CN102171214A (en) 2011-08-31
DK2326650T3 (en) 2014-03-10
PL2326650T3 (en) 2014-07-31
ES2625817T3 (en) 2017-07-20
WO2010017055A3 (en) 2010-05-27
CN104478875A (en) 2015-04-01
US20200261454A1 (en) 2020-08-20
SG10201809895YA (en) 2018-12-28
CY1119218T1 (en) 2018-02-14
GB0913474D0 (en) 2009-09-16
EP2767537A1 (en) 2014-08-20
DK2767537T3 (en) 2017-06-19
CY1115022T1 (en) 2016-12-14
CN103896942A (en) 2014-07-02
FR19C1071I1 (en) 2020-01-17
JP2011530513A (en) 2011-12-22
TW201018688A (en) 2010-05-16
IL211070A (en) 2014-11-30
SI2326650T1 (en) 2014-04-30
US20130190306A1 (en) 2013-07-25
NL301021I1 (en) 2019-12-18
RU2514937C2 (en) 2014-05-10
HUS1900053I1 (en) 2020-02-28
PL2767537T3 (en) 2017-09-29
US8999987B2 (en) 2015-04-07
LTPA2019522I1 (en) 2019-12-27
US8420650B2 (en) 2013-04-16
US8012976B2 (en) 2011-09-06
TW201422617A (en) 2014-06-16
JP5984389B2 (en) 2016-09-06
LT2767537T (en) 2017-08-10
ZA201100897B (en) 2012-06-27
EP2326650B9 (en) 2014-09-10
PT2326650E (en) 2014-05-06
JP2018012698A (en) 2018-01-25
CY2019044I2 (en) 2024-02-16
US9820985B2 (en) 2017-11-21
AR072970A1 (en) 2010-10-06
US10780088B2 (en) 2020-09-22
HK1200813A1 (en) 2015-08-14
SG193842A1 (en) 2013-10-30
US20180117045A1 (en) 2018-05-03
LUC00140I2 (en) 2021-02-12
LTC2767537I2 (en) 2020-11-10
CY2019044I1 (en) 2020-05-29
EP2767537B1 (en) 2017-04-12
CA2732797C (en) 2017-01-03
AU2009279944A1 (en) 2010-02-11
US10543209B2 (en) 2020-01-28
US20100035883A1 (en) 2010-02-11
BRPI0917119B1 (en) 2021-07-13
ES2466565T3 (en) 2014-06-10
NO2019042I1 (en) 2019-11-28
NZ591166A (en) 2012-11-30
TWI448464B (en) 2014-08-11
CN102171214B (en) 2015-06-24
BRPI0917119A2 (en) 2015-11-17
HK1157755A1 (en) 2012-07-06
CA2732797A1 (en) 2010-02-11
US11364241B2 (en) 2022-06-21
US20110237581A1 (en) 2011-09-29
AU2009279944B2 (en) 2014-09-11
EP2326650A4 (en) 2012-03-21
PT2767537T (en) 2017-07-17
JP2015157843A (en) 2015-09-03
US20150209357A1 (en) 2015-07-30
HRP20170982T1 (en) 2017-09-22
GB2462361A (en) 2010-02-10

Similar Documents

Publication Publication Date Title
FR19C1071I2 (en) DIHYDROPYRIDOPHTHALAZINONE POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS
HUS1800022I1 (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
BRPI1007358A2 (en) poly (adp-ribose) polymerase (parp) inhibitors
BRPI0820236A2 (en) Pyridazinone derivatives as parp inhibitors
BRPI0921327A2 (en) Herbicide-Protector Combination
BRPI0919818A2 (en) selective seprase inhibitors
BRPI0917808A2 (en) cmet inhibitors
BRPI0922158A2 (en) nanoemulsions
BRPI0812825A2 (en) FTAAZINONE DERIVATIVES AS PARP-1 INHIBITORS
BRPI0923497A2 (en) pyridazinone derivatives
BRPI0811044A2 (en) 2-MORFOLIN-4-IL-PYRIMIDINES AS P13K INHIBITORS.
BRPI0812387A2 (en) POLYNUCLEOTIDE MACADORS
DK2280962T5 (en) pyridazinone
ATE527260T1 (en) (DIHYDRO)PYRROLOÄ2,1-AÜISOQUINOLINE
BRPI0917673A2 (en) Herbicide-protective combination comprising dimethoxytriazinyl substituted difluoromethanesulfonylanilides
BRPI0716198A2 (en) PYROROLO-ISOKINOLINES AS KINASE INHIBITORS
BRPI0922728A2 (en) herbicide-antidote combination
BRPI0911977A2 (en) substituted quinazolines
BRPI0822141A2 (en) Microfiber
BRPI0912672A2 (en) substituted quinazolines
BRPI0910234A2 (en) 1-butene terpolymers
ITSV20080002A1 (en) SHIFT BUMPERS
ITVA20070044U1 (en) NAPKIN EMBOSSED - NAPKEY EMBRACE
ES1069154Y (en) MOPANISM ESCURRIDOR DE FREGONA